Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV genetic vaccine
- Development stage
- Discontinued
- Lead developer
- Precigen
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
The **RSV genetic vaccine** is a discontinued preclinical-stage vaccine candidate developed by **Precigen** (formerly Intrexon) in collaboration with **Harvest Fund Management**. The program utilized a genetic immunization approach, likely involving DNA or a viral vector (such as Precigen's gorilla adenovirus platform), to deliver sequences encoding **respiratory syncytial virus (RSV)** antigens. The goal was to induce both humoral and cellular immune responses to prevent RSV infection. The program was mentioned in early research publications but was subsequently removed from the active corporate pipeline, indicating it is no longer being pursued for clinical development.
02
Targets
RSV F (Respiratory syncytial virus fusion protein)RSV G (Respiratory syncytial virus attachment glycoprotein)
Beyond the preview
Go deeper on RSV genetic vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV genetic vaccine.